Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7)

Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7)  is a gut‐selective humanized monoclonal antibody targets β7 integrins with a potential to treat inflammatory bowel disease (IBD). MW: 144.3 KD.
Supplier Selleck Chemicals
Product # A2856
Sku # A2856-1mg
Pricing 1mg, $570.00
Feedback